Abstract: Currently, assessing the severity and progression of symptoms in a subject diagnosed with a muscular disability, in particular SMA involves in-clinic monitoring and testing of the subject every 6 to 12 months. However, monitoring and testing a subject more frequently is preferred, but increasing the frequency of in-clinic monitoring and testing can be costly and inconvenient to the subject. Thus, assessing the severity and progression of symptoms via remote monitoring and testing of the subject outside of a clinic environment as described herein provides advantages in cost, ease of monitoring and convenience to the subject. Systems, methods and devices according to the present disclosure provide a diagnostic for assessing of the distal motor function of a subject having a muscular disability, in particular SMA by active testing of the subj ect.

Abstract: Aspects described herein relate to the field of disease tracking and diagnostics. Specifically, they relate to a method of assessing a muscular disability and, in particular, spinal muscular atrophy (SMA) in a subject comprising the steps of determining at least one parameter from a dataset of sensor measurements of the subject using a mobile device, and comparing the determined at least one parameter to a reference, whereby the muscular disability and, in particular, SMA will be assessed. Aspects described herein also relate to a mobile device comprising a processor, at least one pressure sensor and a database as well as software which is tangibly embedded to said device and, when running on said device, carries out the method of the invention as well as the use of such a device for assessing a muscular disability and, in particular, SMA.

Abstract: Currently, assessing the severity and progression of symptoms in a subject diagnosed with a muscular disability, in particular SMA involves in-clinic monitoring and testing of the subject every 6 to 12 months. However, monitoring and testing a subject more frequently is preferred, but increasing the frequency of in-clinic monitoring and testing can be costly and inconvenient to the subject. Thus, assessing the severity and progression of symptoms via remote monitoring and testing of the subject outside of a clinic environment as described herein provides advantages in cost, ease of monitoring and convenience to the subject. Systems, methods and devices according to the present disclosure provide a diagnostic for assessing of the axial motor function of a subject having a muscular disability, in particular SMA by active testing of the subject.

Abstract: Currently, assessing the severity and progression of symptoms in a subject diagnosed with a muscular disability, in particular SMA involves in-clinic monitoring and testing of the subject every 6 to 12 months. However, monitoring and testing a subject more frequently is preferred, but increasing the frequency of in-clinic monitoring and testing can be costly and inconvenient to the subject. Thus, assessing the severity and progression of symptoms via remote monitoring and testing of the subject outside of a clinic environment as described herein provides advantages in cost, ease of monitoring and convenience to the subject. Systems, methods and devices according to the present disclosure provide a diagnostic for assessing of the axial motor function of a subject having a muscular disability, in particular SMA by active testing of the subject.

Abstract: Currently, assessing the severity and progression of symptoms in a subject diagnosed with a muscular disability, in particular SMA involves in-clinic monitoring and testing of the subject every 6 to 12 months. However, monitoring and testing a subject more frequently is preferred, but increasing the frequency of in-clinic monitoring and testing can be costly and inconvenient to the subject. Thus, assessing the severity and progression of symptoms via remote monitoring and testing of the subject outside of a clinic environment as described herein provides advantages in cost, ease of monitoring and convenience to the subject. Systems, methods and devices according to the present disclosure provide a diagnostic for assessing of the distal hypotonia of a subject having a muscular disability, in particular SMA by active testing of the subject.

Abstract: Currently, assessing the severity and progression of symptoms in a subject diagnosed with a muscular disability, in particular SMA involves in-clinic monitoring and testing of the subject every 6 to 12 months. However, monitoring and testing a subject more frequently is preferred, but increasing the frequency of in-clinic monitoring and testing can be costly and inconvenient to the subject. Thus, assessing the severity and progression of symptoms via remote monitoring and testing of the subject outside of a clinic environment as described herein provides advantages in cost, ease of monitoring and convenience to the subject. Systems, methods and devices according to the present disclosure provide a diagnostic for assessing of the axial motor function of a subject having a muscular disability, in particular SMA by active testing of the subject.

Abstract: Currently, assessing the severity and progression of symptoms in a subject diagnosed with a muscular disability, in particular SMA involves in-clinic monitoring and testing of the subject every 6 to 12 months. However, monitoring and testing a subject more frequently is preferred, but increasing the frequency of in-clinic monitoring and testing can be costly and inconvenient to the subject. Thus, assessing the severity and progression of symptoms via remote monitoring and testing of the subject outside of a clinic environment as described herein provides advantages in cost, ease of monitoring and convenience to the subject. Systems, methods and devices according to the present disclosure provide a diagnostic for assessing of the distal motor function of a subject having a muscular disability, in particular SMA by active testing of the subject.

Abstract: Currently, assessing the severity and progression of symptoms in a patient diagnosed with Alzheimer's disease involves in-clinic monitoring and testing of the patient every 6 to 12 months. However, monitoring and testing a patient more frequently is preferred, but increasing the frequency of in-clinic monitoring and testing can be costly and inconvenient to the patient. Thus, assessing the severity and progression of symptoms via remote monitoring and testing of the patient outside of a clinic environment as described herein provides advantages in cost, ease of monitoring, ecological validity, reliability and convenience to the patient, like improvement of quality of life. Systems, methods and devices according to the present disclosure provide a diagnostic for assessing one or more pre-clinical signs and/or symptoms of Alzheimer's disease in a patient by passive monitoring of the patient and/or active testing of the patient.

Abstract: Currently, assessing the severity and progression of symptoms in a patient diagnosed with Huntington's disease involves in-clinic monitoring and testing of the patient every 6 to 12 months. However, monitoring and testing a patient more frequently is preferred, but increasing the frequency of in-clinic monitoring and testing can be costly and inconvenient to the patient. Thus, assessing the severity and progression of symptoms via remote monitoring and testing of the patient outside of a clinic environment as described herein provides advantages in cost, ease of monitoring and convenience to the patient. Systems, methods and devices according to the present disclosure provide a diagnostic for assessing one or more symptoms of Huntington's disease in a patient by passive monitoring of the patient and/or active testing of the patient.

Abstract: The present disclosure relates to the field of schizophrenia or an autism spectrum disorder (“ASD”) diagnostics and disease management. Specifically, the present disclosure teaches a method of assessing schizophrenia or ASD in a subject in which a subject's usage data for a mobile device is collected over a first predefined time window. A usage behavior parameter is determined from the usage data, and the determined usage behavior parameter is compared to a reference. From the comparison it may be determined whether the schizophrenia or ASD in the subject is improving, persisting or worsening. A system including a mobile device having sensors recording usage data and a remote device operatively linked to the mobile device is also disclosed.

Abstract: The present disclosure relates to the field of schizophrenia or an autism spectrum disorder (“ASD”) diagnostics and disease management. Specifically, the present disclosure teaches a method of assessing schizophrenia or ASD in a subject in which a subject's usage data for a mobile device is collected over a first predefined time window. A usage behavior parameter is determined from the usage data, and the determined usage behavior parameter is compared to a reference. From the comparison it may be determined whether the schizophrenia or ASD in the subject is improving, persisting or worsening. A system including a mobile device having sensors recording usage data and a remote device operatively linked to the mobile device is also disclosed.

Abstract: A method for automatically assessing information processing speed in a test subject is disclosed. In the inventive method, a first qualimetric activity parameter for sensorial transmission, cognition and motoric output activity is determined and a second qualimetric activity parameter for sensorial transmission and motoric output activity is determined. A third qualimetric activity parameter for cognition is determined by comparing the first and the second qualimetric activity parameters to each other, and the information processing speed in the test subject is assessed based on the first, second and third qualimetric activity parameters. The information processing speed can be determined by comparing the determined qualimetric activity parameters to a reference and the subject's cognitive impairment can then be determined from the processing speed. The inventive method can be computer implemented. A mobile device or system for carrying out the disclosed methods is also disclosed.

Abstract: A method of assessing a muscular disability and, preferably, spinal muscular atrophy (SMA) in a subject is disclosed. A performance parameter is determined from a dataset of pressure measurements of the individual finger strength from the subject using a mobile device and is compared to a reference whereby the muscular disability and, preferably, SMA is assessed.

Abstract: Disclosed is a method for assessing a cognition and movement disease or disorder in a subject. In the method, a qualimetric activity parameter for cognition and/or fine motoric activity measurements is determined from a dataset of measurements obtained from the subject using a mobile device. The qualimetric activity parameter is compared to a reference and the disease or disorder is thereby assessed. A method identifying whether a subject will benefit from a therapy for a cognition and movement disease or disorder is also disclosed. The method can be carried out with a mobile device having a processor, a sensor and a database as well as software that carries out the method. Also disclosed is a system having a mobile device with a sensor and a remote device having a processor and a database and software that carries out the method for assessing a cognition and movement disease or disorder.

Abstract: The present disclosure relates to the field of diagnostics, specifically, to a method of identifying progressing multiple sclerosis (MS) in a subject. At least one performance parameter is determined from a dataset of activity measurements obtained from the subject using a mobile device, and the performance parameter is compared to a reference, whereby a subject with progressing MS will be identified. Also disclosed is a method of recommending an anti-CD20 antibody therapy against MS that includes the steps just mentioned and the further step of recommending the anti-CD20 antibody therapy if the subject suffers from progressing MS. Also disclosed is a mobile device having a processor, at least one sensor and a database as well as software which is tangibly embedded to the device and, when running on said device, carries out the method of this disclosure as well as the use of such a device for identifying a subject suffering from progressing MS.

Abstract: A method for assessing a cognition and movement disease or disorder in a subject suspected to suffer therefrom. A cognition and/or fine motoric activity parameter is determined from a dataset of activity measurements obtained from the subject using a mobile device. The determined activity parameter is compared to a reference, and the cognition and movement disease or disorder is assessed. Also disclosed is a method for identifying whether a subject will benefit from a therapy for a cognition and movement disease or disorder. The steps just described are performed along with the step of identifying the subject as one who benefits from the therapy if the cognition and movement disease or disorder is assessed. Also disclosed is a mobile device comprising a processor, at least one sensor, a database and software which is tangibly embedded in said device and, when running on said device, carries out the disclosed methods.

Abstract: The present invention is directed to an arginine/lysine oxidoreductase modified with polyethylene glycol, a production method thereof, and methods of treating disorders responsive to a modification of amino acid levels reactive oxygen species and/or ammonium.

Abstract: The present invention is directed to an arginine/lysine oxidoreductase modified with polyethylene glycol, a production method thereof, and methods of treating disorders responsive to a modification of amino acid levels reactive oxygen species and/or ammonium.

Abstract: The invention relates to an adjustment device of an automotive vehicle. It comprises a movable adjustment part the position of which is adjustable according to the user's wishes. The adjustment part comprises at least a first piece and a second piece. These pieces are fixedly joined together in a connection region. Each piece comprises a border that is connected to the border of the other piece in the connection region. One piece may be made from a higher quality material and the other piece from a lower quality material. One piece may be made from a thinner material and the other piece from a thicker material.

Abstract: The present invention is directed to an arginine/lysine oxidoreductase modified with polyethylene glycol and to a production method thereof and to methods of treating disorders responsive to a modification of amino acid levels reactive oxygen species and/or ammonium.